Buch, Englisch, Band 86, 320 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 594 g
Reihe: Advances in Pharmacology
Buch, Englisch, Band 86, 320 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 594 g
Reihe: Advances in Pharmacology
ISBN: 978-0-12-816668-0
Verlag: ACADEMIC PR INC
Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more.
Zielgruppe
<p>investigators in neuroscience, pharmacology, neurology, psychiatry, medicine. </p>
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
- Sozialwissenschaften Psychologie Psychotherapie / Klinische Psychologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Neuropharmakologie, Psychopharmakologie
Weitere Infos & Material
1. GPCR drug discovery-moving beyond the orthosteric to the allosteric domainChristian C. Felder2. Lipid rafts in psychiatryNathan H. Wray and Mark M. Rasenick3. Rapid-acting antidepressantsJeffrey M. Witkin, Anna E. Martin, Lalit K. Golani, Nina Z. Xu and Jodi L. Smith4. mGlu2/3 receptor antagonistsShigeyuki Chaki5. Nitric oxide: Antidepressant mechanisms and inflammationMehdi Ghasemi6. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disordersLaura B. Teal, Robert W. Gould, Andrew S. Felts and Carrie K. Jones7. Medications development for food-based and drug use disordersFernando B. de Moura, Stephen J. Kohut and Jack Bergman8. Obsessive compulsive disorder (OCD): Current treatments and a framework for neurotherapeutic researchErik Z. Woody, Kurt Leroy Hoffman and Henry Szechtman9. Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disordersKjell A. Svensson, Junliang Hao and Robert F. Bruns
